KRAS and infection: Among patients with HCV GT2b infection who experienced VF in studies M12‐536 or GIFT‐II, treatment‐emergent substitutions at amino acid position D168 in NS3 remained detectable in 74.3% (26/35) and 25.0% (8/32) of patients with available sequence at post‐treatment week 24 and 48, respectively.